Loading…
Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis
Despite several studies that have estimated the economic impact of Respiratory Syncytial Virus (RSV) in infants, limited data are available on healthcare resource use and costs attributable to RSV across age groups. The aim of this study was to quantify age-specific RSV-related healthcare resource u...
Saved in:
| Published in: | BMC health services research 2018-04, Vol.18 (1), p.294-294, Article 294 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c598t-308f17b789ee18bb6e747b3cf6da7926071083334ac3c6018b72ccb1db0d48103 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c598t-308f17b789ee18bb6e747b3cf6da7926071083334ac3c6018b72ccb1db0d48103 |
| container_end_page | 294 |
| container_issue | 1 |
| container_start_page | 294 |
| container_title | BMC health services research |
| container_volume | 18 |
| creator | Amand, Caroline Tong, Sabine Kieffer, Alexia Kyaw, Moe H |
| description | Despite several studies that have estimated the economic impact of Respiratory Syncytial Virus (RSV) in infants, limited data are available on healthcare resource use and costs attributable to RSV across age groups. The aim of this study was to quantify age-specific RSV-related healthcare resource use and costs on the US healthcare system.
This retrospective case-control study identified patients aged ≥1 year with an RSV event in the Truven Health Marketscan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases between August 31, 2012 and August 1, 2013. RSV patients were matched 1:1 with non-RSV controls for age, gender, region, healthcare plan and index date (n = 11,432 in each group). Stratified analyses for healthcare resource use and costs were conducted by age groups. RSV-attributable resource use and costs were assessed based on the incremental differences between RSV cases and controls using multivariate analysis.
RSV patients had a higher healthcare resource use (hospital stays, emergency room/urgent care visits, ambulatory visits and outpatient visits) than non-RSV matched controls for all age groups (all p |
| doi_str_mv | 10.1186/s12913-018-3066-1 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9c95456024d94983930553e4546a8a59</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546834290</galeid><doaj_id>oai_doaj_org_article_9c95456024d94983930553e4546a8a59</doaj_id><sourcerecordid>A546834290</sourcerecordid><originalsourceid>FETCH-LOGICAL-c598t-308f17b789ee18bb6e747b3cf6da7926071083334ac3c6018b72ccb1db0d48103</originalsourceid><addsrcrecordid>eNptks9u1DAQxiMEoqXwAFyQJS5cUuw4_scBqaqAVqrEAXq2Js5k11XWXmyn0r5BHxtvt1SthHywNf6-n2fG0zTvGT1lTMvPmXWG8ZYy3XIqZcteNMesV10rjeQvn5yPmjc531DKlO7U6-aoM1JpptRxc3eBMJe1g4QkYY5LckiWjATCSNDFEDfekWFJIwYCpSQ_LAWGGUmJe8PWJygx7UjeBbcrHmZy69OSiQ-krJFcB19wJL8KFMxfCBA3g99kMkKlwP07MO-yz2-bVxPMGd897CfN9fdvv88v2qufPy7Pz65aJ4wutU49MTUobRCZHgaJqlcDd5McQZlOUsWo5pz34LiTtTOD6pwb2DjQsdeM8pPm8sAdI9zYbfIbSDsbwdv7QEwrC6l4N6M1zoheSNr1o-mN5oZTITj2opegQZjK-npgbZdhg6PDUBLMz6DPb4Jf21W8tcIwKpSogE8PgBT_LJiL3fjscJ4hYFyy7WinjaC876r040G6gpqaD1OsRLeX27OakK4as6_u9D-qukas_xgDTr7GnxnYweBSzDnh9Jg9o3Y_ZPYwZLa20u6HzLLq-fC07EfHv6nifwHfyc2i</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2028950342</pqid></control><display><type>article</type><title>Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis</title><source>Publicly Available Content Database</source><source>ABI/INFORM Global</source><source>PubMed Central</source><creator>Amand, Caroline ; Tong, Sabine ; Kieffer, Alexia ; Kyaw, Moe H</creator><creatorcontrib>Amand, Caroline ; Tong, Sabine ; Kieffer, Alexia ; Kyaw, Moe H</creatorcontrib><description>Despite several studies that have estimated the economic impact of Respiratory Syncytial Virus (RSV) in infants, limited data are available on healthcare resource use and costs attributable to RSV across age groups. The aim of this study was to quantify age-specific RSV-related healthcare resource use and costs on the US healthcare system.
This retrospective case-control study identified patients aged ≥1 year with an RSV event in the Truven Health Marketscan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases between August 31, 2012 and August 1, 2013. RSV patients were matched 1:1 with non-RSV controls for age, gender, region, healthcare plan and index date (n = 11,432 in each group). Stratified analyses for healthcare resource use and costs were conducted by age groups. RSV-attributable resource use and costs were assessed based on the incremental differences between RSV cases and controls using multivariate analysis.
RSV patients had a higher healthcare resource use (hospital stays, emergency room/urgent care visits, ambulatory visits and outpatient visits) than non-RSV matched controls for all age groups (all p < 0.0001), particularly in the elderly age groups with RSV (1.9 to 3 days length of stay, 0.4 to 0.5 more ER/UC visits, 0.7 to 2.7 more ambulatory visits, 12.1 to 18.6 more outpatient visits and 9.5 to 14.6 more prescriptions than elderly in the control groups). The incremental difference in adjusted mean annual costs between RSV and non-RSV controls was higher in elderly (≥65; $12,030 to $23,194) than in those aged < 65 years ($2251 to $5391). Among children, adjusted costs attributable to RSV were higher in children aged 5-17 years ($3192), than those 1-4 years ($2251 to $2521).
Our findings showed a substantial annual RSV-attributable healthcare resource use and costs in the US across age groups, with the highest burden in those aged ≥65 years. These data can be used in cost-effectiveness analyses, and may be useful for policymakers to guide future RSV vaccination and other prevention programs.</description><identifier>ISSN: 1472-6963</identifier><identifier>EISSN: 1472-6963</identifier><identifier>DOI: 10.1186/s12913-018-3066-1</identifier><identifier>PMID: 29678177</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Analysis ; Care and treatment ; Case-Control Studies ; Child ; Cost-Benefit Analysis ; Databases, Factual ; Economic aspects ; Economic burden ; Female ; Health aspects ; Health Resources - economics ; Healthcare costs ; Healthcare resource use ; Hospitalization - economics ; Humans ; Infant ; Infants ; Insurance, Health, Reimbursement - statistics & numerical data ; Length of Stay - economics ; Length of Stay - statistics & numerical data ; Male ; Medical care, Cost of ; Medicare ; Middle Aged ; Primary Prevention - economics ; Respiratory syncytial virus infection ; Respiratory Syncytial Virus Infections - economics ; Respiratory Syncytial Virus Infections - epidemiology ; Respiratory Syncytial Virus Infections - prevention & control ; Retrospective Studies ; RSV ; United States - epidemiology ; Vaccines</subject><ispartof>BMC health services research, 2018-04, Vol.18 (1), p.294-294, Article 294</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c598t-308f17b789ee18bb6e747b3cf6da7926071083334ac3c6018b72ccb1db0d48103</citedby><cites>FETCH-LOGICAL-c598t-308f17b789ee18bb6e747b3cf6da7926071083334ac3c6018b72ccb1db0d48103</cites><orcidid>0000-0002-0258-6645</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910575/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910575/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,36042,36994,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29678177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Amand, Caroline</creatorcontrib><creatorcontrib>Tong, Sabine</creatorcontrib><creatorcontrib>Kieffer, Alexia</creatorcontrib><creatorcontrib>Kyaw, Moe H</creatorcontrib><title>Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis</title><title>BMC health services research</title><addtitle>BMC Health Serv Res</addtitle><description>Despite several studies that have estimated the economic impact of Respiratory Syncytial Virus (RSV) in infants, limited data are available on healthcare resource use and costs attributable to RSV across age groups. The aim of this study was to quantify age-specific RSV-related healthcare resource use and costs on the US healthcare system.
This retrospective case-control study identified patients aged ≥1 year with an RSV event in the Truven Health Marketscan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases between August 31, 2012 and August 1, 2013. RSV patients were matched 1:1 with non-RSV controls for age, gender, region, healthcare plan and index date (n = 11,432 in each group). Stratified analyses for healthcare resource use and costs were conducted by age groups. RSV-attributable resource use and costs were assessed based on the incremental differences between RSV cases and controls using multivariate analysis.
RSV patients had a higher healthcare resource use (hospital stays, emergency room/urgent care visits, ambulatory visits and outpatient visits) than non-RSV matched controls for all age groups (all p < 0.0001), particularly in the elderly age groups with RSV (1.9 to 3 days length of stay, 0.4 to 0.5 more ER/UC visits, 0.7 to 2.7 more ambulatory visits, 12.1 to 18.6 more outpatient visits and 9.5 to 14.6 more prescriptions than elderly in the control groups). The incremental difference in adjusted mean annual costs between RSV and non-RSV controls was higher in elderly (≥65; $12,030 to $23,194) than in those aged < 65 years ($2251 to $5391). Among children, adjusted costs attributable to RSV were higher in children aged 5-17 years ($3192), than those 1-4 years ($2251 to $2521).
Our findings showed a substantial annual RSV-attributable healthcare resource use and costs in the US across age groups, with the highest burden in those aged ≥65 years. These data can be used in cost-effectiveness analyses, and may be useful for policymakers to guide future RSV vaccination and other prevention programs.</description><subject>Aged</subject><subject>Analysis</subject><subject>Care and treatment</subject><subject>Case-Control Studies</subject><subject>Child</subject><subject>Cost-Benefit Analysis</subject><subject>Databases, Factual</subject><subject>Economic aspects</subject><subject>Economic burden</subject><subject>Female</subject><subject>Health aspects</subject><subject>Health Resources - economics</subject><subject>Healthcare costs</subject><subject>Healthcare resource use</subject><subject>Hospitalization - economics</subject><subject>Humans</subject><subject>Infant</subject><subject>Infants</subject><subject>Insurance, Health, Reimbursement - statistics & numerical data</subject><subject>Length of Stay - economics</subject><subject>Length of Stay - statistics & numerical data</subject><subject>Male</subject><subject>Medical care, Cost of</subject><subject>Medicare</subject><subject>Middle Aged</subject><subject>Primary Prevention - economics</subject><subject>Respiratory syncytial virus infection</subject><subject>Respiratory Syncytial Virus Infections - economics</subject><subject>Respiratory Syncytial Virus Infections - epidemiology</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Retrospective Studies</subject><subject>RSV</subject><subject>United States - epidemiology</subject><subject>Vaccines</subject><issn>1472-6963</issn><issn>1472-6963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptks9u1DAQxiMEoqXwAFyQJS5cUuw4_scBqaqAVqrEAXq2Js5k11XWXmyn0r5BHxtvt1SthHywNf6-n2fG0zTvGT1lTMvPmXWG8ZYy3XIqZcteNMesV10rjeQvn5yPmjc531DKlO7U6-aoM1JpptRxc3eBMJe1g4QkYY5LckiWjATCSNDFEDfekWFJIwYCpSQ_LAWGGUmJe8PWJygx7UjeBbcrHmZy69OSiQ-krJFcB19wJL8KFMxfCBA3g99kMkKlwP07MO-yz2-bVxPMGd897CfN9fdvv88v2qufPy7Pz65aJ4wutU49MTUobRCZHgaJqlcDd5McQZlOUsWo5pz34LiTtTOD6pwb2DjQsdeM8pPm8sAdI9zYbfIbSDsbwdv7QEwrC6l4N6M1zoheSNr1o-mN5oZTITj2opegQZjK-npgbZdhg6PDUBLMz6DPb4Jf21W8tcIwKpSogE8PgBT_LJiL3fjscJ4hYFyy7WinjaC876r040G6gpqaD1OsRLeX27OakK4as6_u9D-qukas_xgDTr7GnxnYweBSzDnh9Jg9o3Y_ZPYwZLa20u6HzLLq-fC07EfHv6nifwHfyc2i</recordid><startdate>20180420</startdate><enddate>20180420</enddate><creator>Amand, Caroline</creator><creator>Tong, Sabine</creator><creator>Kieffer, Alexia</creator><creator>Kyaw, Moe H</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0258-6645</orcidid></search><sort><creationdate>20180420</creationdate><title>Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis</title><author>Amand, Caroline ; Tong, Sabine ; Kieffer, Alexia ; Kyaw, Moe H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c598t-308f17b789ee18bb6e747b3cf6da7926071083334ac3c6018b72ccb1db0d48103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Analysis</topic><topic>Care and treatment</topic><topic>Case-Control Studies</topic><topic>Child</topic><topic>Cost-Benefit Analysis</topic><topic>Databases, Factual</topic><topic>Economic aspects</topic><topic>Economic burden</topic><topic>Female</topic><topic>Health aspects</topic><topic>Health Resources - economics</topic><topic>Healthcare costs</topic><topic>Healthcare resource use</topic><topic>Hospitalization - economics</topic><topic>Humans</topic><topic>Infant</topic><topic>Infants</topic><topic>Insurance, Health, Reimbursement - statistics & numerical data</topic><topic>Length of Stay - economics</topic><topic>Length of Stay - statistics & numerical data</topic><topic>Male</topic><topic>Medical care, Cost of</topic><topic>Medicare</topic><topic>Middle Aged</topic><topic>Primary Prevention - economics</topic><topic>Respiratory syncytial virus infection</topic><topic>Respiratory Syncytial Virus Infections - economics</topic><topic>Respiratory Syncytial Virus Infections - epidemiology</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Retrospective Studies</topic><topic>RSV</topic><topic>United States - epidemiology</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amand, Caroline</creatorcontrib><creatorcontrib>Tong, Sabine</creatorcontrib><creatorcontrib>Kieffer, Alexia</creatorcontrib><creatorcontrib>Kyaw, Moe H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC health services research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amand, Caroline</au><au>Tong, Sabine</au><au>Kieffer, Alexia</au><au>Kyaw, Moe H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis</atitle><jtitle>BMC health services research</jtitle><addtitle>BMC Health Serv Res</addtitle><date>2018-04-20</date><risdate>2018</risdate><volume>18</volume><issue>1</issue><spage>294</spage><epage>294</epage><pages>294-294</pages><artnum>294</artnum><issn>1472-6963</issn><eissn>1472-6963</eissn><abstract>Despite several studies that have estimated the economic impact of Respiratory Syncytial Virus (RSV) in infants, limited data are available on healthcare resource use and costs attributable to RSV across age groups. The aim of this study was to quantify age-specific RSV-related healthcare resource use and costs on the US healthcare system.
This retrospective case-control study identified patients aged ≥1 year with an RSV event in the Truven Health Marketscan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases between August 31, 2012 and August 1, 2013. RSV patients were matched 1:1 with non-RSV controls for age, gender, region, healthcare plan and index date (n = 11,432 in each group). Stratified analyses for healthcare resource use and costs were conducted by age groups. RSV-attributable resource use and costs were assessed based on the incremental differences between RSV cases and controls using multivariate analysis.
RSV patients had a higher healthcare resource use (hospital stays, emergency room/urgent care visits, ambulatory visits and outpatient visits) than non-RSV matched controls for all age groups (all p < 0.0001), particularly in the elderly age groups with RSV (1.9 to 3 days length of stay, 0.4 to 0.5 more ER/UC visits, 0.7 to 2.7 more ambulatory visits, 12.1 to 18.6 more outpatient visits and 9.5 to 14.6 more prescriptions than elderly in the control groups). The incremental difference in adjusted mean annual costs between RSV and non-RSV controls was higher in elderly (≥65; $12,030 to $23,194) than in those aged < 65 years ($2251 to $5391). Among children, adjusted costs attributable to RSV were higher in children aged 5-17 years ($3192), than those 1-4 years ($2251 to $2521).
Our findings showed a substantial annual RSV-attributable healthcare resource use and costs in the US across age groups, with the highest burden in those aged ≥65 years. These data can be used in cost-effectiveness analyses, and may be useful for policymakers to guide future RSV vaccination and other prevention programs.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>29678177</pmid><doi>10.1186/s12913-018-3066-1</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0258-6645</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1472-6963 |
| ispartof | BMC health services research, 2018-04, Vol.18 (1), p.294-294, Article 294 |
| issn | 1472-6963 1472-6963 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_9c95456024d94983930553e4546a8a59 |
| source | Publicly Available Content Database; ABI/INFORM Global; PubMed Central |
| subjects | Aged Analysis Care and treatment Case-Control Studies Child Cost-Benefit Analysis Databases, Factual Economic aspects Economic burden Female Health aspects Health Resources - economics Healthcare costs Healthcare resource use Hospitalization - economics Humans Infant Infants Insurance, Health, Reimbursement - statistics & numerical data Length of Stay - economics Length of Stay - statistics & numerical data Male Medical care, Cost of Medicare Middle Aged Primary Prevention - economics Respiratory syncytial virus infection Respiratory Syncytial Virus Infections - economics Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Retrospective Studies RSV United States - epidemiology Vaccines |
| title | Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T20%3A47%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Healthcare%20resource%20use%20and%20economic%20burden%20attributable%20to%20respiratory%20syncytial%20virus%20in%20the%20United%20States:%20a%20claims%20database%20analysis&rft.jtitle=BMC%20health%20services%20research&rft.au=Amand,%20Caroline&rft.date=2018-04-20&rft.volume=18&rft.issue=1&rft.spage=294&rft.epage=294&rft.pages=294-294&rft.artnum=294&rft.issn=1472-6963&rft.eissn=1472-6963&rft_id=info:doi/10.1186/s12913-018-3066-1&rft_dat=%3Cgale_doaj_%3EA546834290%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c598t-308f17b789ee18bb6e747b3cf6da7926071083334ac3c6018b72ccb1db0d48103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2028950342&rft_id=info:pmid/29678177&rft_galeid=A546834290&rfr_iscdi=true |